

January 05, 2026

**To,**  
**Dy. General Manager**  
**Department of Corporate Services,**  
**BSE Ltd.**  
**Phiroze Jeejeebhoy Towers**  
**Dalal Street, Fort, Mumbai – 400 001**

**Ref: Scrip Code: 532296**

**To,**  
**The Manager – Listing,**  
**The National Stock Exchange of India Ltd.,**  
**Plot No. C/1, G Block**  
**Bandra Kurla Complex,**  
**Bandra (E), Mumbai – 400 051**

**Ref: Scrip Name: GLENMARK**

Dear Sir,

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) – ESG Rating**

Pursuant to Regulation 30 of the SEBI Listing Regulations, 2015 read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, we wish to inform you that SES ESG Research Private Limited vide its email dated January 04, 2026, has assigned an ESG rating of “71.1” for F.Y. 2025.

We hereby clarify that the Company has not engaged SES ESG for ESG Rating. SES ESG has independently assigned the rating based on publicly available information for F.Y. 2025.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
**For Glenmark Pharmaceuticals Limited**

**Harish Kuber**  
**Company Secretary & Compliance Officer**

**Glenmark Pharmaceuticals Limited**

Glenmark House, B. D. Sawant Marg, Andheri (East), Mumbai 400 099, India

T: +91 22 4018 9999 F: +91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)